Fig. 1 · Structure

Documents & Downloads

Tolfenamic acid

Cat. No. A11693 CAS 13710-19-5

COX-2 inhibitor

Tolfenamic Acid is a COX-2 inhibitor with IC50 of 0.2 μM. It is one of the class of non-steroidal anti-inflammatory drugs (NSAIDs). It is used to treat the symptoms of migraine.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
COX-2 13.49 μM (IC50, in cell)

Tolfenamic acid Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Tolfenamic acid from 3 published references. In vitro models include L3.6pl pancreatic cancer cells; MIA PaCa-2.

Tolfenamic acid In Vitro Studies

Tolfenamic acid treatment at 50 μM for 48 h produced predominantly downregulated genes in L3.6pl pancreatic cancer cells, with 704 down versus 253 up. Under the same treatment conditions, MIA PaCa-2 cells showed predominantly upregulated genes, with 211 up versus 107 down. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Genes differentially expressed by TA treatment in L3.6pl cells

Cell-based study · L3.6pl pancreatic cancer cells [1]

L3.6pl pancreatic cancer cells were treated with Tolfenamic acid at 50 μM for 48 h, with equivalent DMSO treatment as the control. Differential gene expression analysis showed predominantly downregulated genes: 704 down versus 253 up.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Differential gene expressiondifferentially expressed genes 704 down vs. 253 up[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM
Exposure duration
48 h
Method
added directly to the media
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Tolfenamic acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Genes expression regulation by TA treatment (S1, S11); MATERIALS AND METHODS > Cell lines (S33); MATERIALS AND METHODS > Treatment (S36, S38, S39); MATERIALS AND METHODS > Microarray analysis (S40)

Differential gene expression: Differential gene expression; comparator: Control cells were treated with equivalent amounts of DMSO. — RESULTS > Genes expression regulation by TA treatment (S1, S11); MATERIALS AND METHODS > Microarray analysis (S40)

Genes affected by TA in MIA PaCa-2

Cell-based study · MIA PaCa-2 [1]

MIA PaCa-2 cells were treated with Tolfenamic acid at 50 μM for 48 h, with equivalent DMSO treatment as the control. Differential gene expression analysis showed predominantly upregulated genes: 211 up versus 107 down.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Differential gene expressiondifferentially expressed genes 211 up vs. 107 down[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM
Exposure duration
48 h
Method
added directly to the media
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Tolfenamic acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Genes expression regulation by TA treatment (S1, S11); MATERIALS AND METHODS > Cell lines (S31); MATERIALS AND METHODS > Treatment (S36, S38, S39); MATERIALS AND METHODS > Microarray analysis (S40)

Differential gene expression: Differential gene expression; comparator: Control cells were treated with equivalent amounts of DMSO. — RESULTS > Genes expression regulation by TA treatment (S1, S11); MATERIALS AND METHODS > Microarray analysis (S40)

Tolfenamic acid In Vivo Studies

In R6/1 mice, oral Tolfenamic acid administered by gavage at 25 mg/kg or 50 mg/kg was associated with greater exploration distances than in the model group. In P12 rats, Tolfenamic acid at 50 mg/kg by intraperitoneal injection significantly decreased brain p-tau expression at 4 and 6 h after injection. [2,3]

Exploration distance in Huntington model mice

Animal study · B6.Cg-Tg(HDexon1)61Gpb/JNju mice (i.e., R6/1); n = 7 or 8 [2]

R6/1 mice received Tolfenamic acid orally by gavage at 25 mg/kg or 50 mg/kg. Exploration distances were 6000.28 ± 757.01 mm and 7674.76 ± 1149.21 mm, respectively, compared with 2699.30 ± 674.67 mm in the model group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Exploration distance (mm)Exploration distance 6000.28 ± 757.01 mm; 7674.76 ± 1149.21 mm[2]

Conditions shared by the study groups

Route
orally administered tolfenamic acid or vehicle by gavage
Treatment course
Ten-week-old mice; when the mice were 20 weeks old
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tolfenamic acid 25 mg/kg; 50 mg/kgR6/1 mice (model group)TA 25 mg/kg: 6000.28 ± 757.01 mm; TA 50 mg/kg: 7674.76 ± 1149.21 mm; Model: 2699.30 ± 674.67 mm; p < 0.05 and p < 0.01 vs. the model group[2]
Tolfenamic acid 25 mg/kg; 50 mg/kg
Model: B6.Cg-Tg(HDexon1)61Gpb/JNju mice (i.e., R6/1); n = 7 or 8
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Tolfenamic acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.2. Animals (S7); 2. Materials and Methods > 2.3. Drug and Treatment Schedule (S12, S13); 2. Materials and Methods > 2.4. Locomotor Behavior Test (S18); Table 1 legend (S182); Table 1 (T1.h1, T1.r2, T1.r3, T1.r4)

Exploration distance (mm): Exploration distance (mm); comparator: R6/1 mice (model group) — Table 1 legend (S182); Table 1 (T1.h1, T1.r2, T1.r3, T1.r4)

Tolfenamic acid 25 mg/kg; 50 mg/kg · 2. Materials and Methods > 2.3. Drug and Treatment Schedule (S12, S13); 2. Materials and Methods > 2.4. Locomotor Behavior Test (S18); Table 1 legend (S182); Table 1 (T1.h1, T1.r2, T1.r3, T1.r4)

Reduced Brain Phosphorylated Tau Expression in Rats

Animal study · P12 rats; n = 5 [3]

P12 rats received Tolfenamic acid at 50 mg/kg by intraperitoneal injection. Brain western blotting showed significantly decreased p-tau expression at 4 and 6 h after injection.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
western blotting for semi-quantification of the p-tau level in the brainReported result Tolfenamic acid treatment (50 mg/kg, i.p.) for 4 and 6 h significantly decreased the expression of p-tau (Ser-202 and Ser-396).[3]

Conditions shared by the study groups

Route
injected i.p.
Treatment course
4 and 6 h after injection
Vehicle
5% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tolfenamic acid 50 mg/kg0 hTolfenamic acid treatment (50 mg/kg, i.p.) for 4 and 6 h significantly decreased the expression of p-tau (Ser-202 and Ser-396).[3]
Tolfenamic acid 50 mg/kg
Model: P12 rats; n = 5
Methods and source locations

Compound reported in the paper: Tolfenamic acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Treatment schedule (S15, S16); Results > Tolfenamic acid attenuated tau hyperphosphorylation in postnatal rats (S81); Fig. 2 legend (S129, S130)

western blotting for semi-quantification of the p-tau level in the brain: western blotting for semi-quantification of the p-tau level in the brain; comparator: 0 h — Results > Tolfenamic acid attenuated tau hyperphosphorylation in postnatal rats (S81); Fig. 2 legend (S129)

Tolfenamic acid 50 mg/kg · Materials and methods > Treatment schedule (S15, S16); Fig. 2 legend (S129)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 13710-19-5
Applications COX-2 inhibitor
Formula C14H12ClNO2
Molecular Weight 261.7
Synonyms TA
SMILES
CC1=C(C=CC=C1Cl)NC2=CC=CC=C2C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 50 mg/mL (191.06 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Tolfenamic acid Research References

  1. [1] Sankpal UT, Goodison S, Jones-Pauley M, et al. Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells. Oncotarget (2017). PMID: 28099934 DOI: 10.18632/oncotarget.14651 Source material
  2. [2] Liu P, Li Y, Yang W, et al. Prevention of Huntington's Disease-Like Behavioral Deficits in R6/1 Mouse by Tolfenamic Acid Is Associated with Decreases in Mutant Huntingtin and Oxidative Stress. Oxid Med Cell Longev (2019). PMID: 31049134 DOI: 10.1155/2019/4032428 Source material
  3. [3] Zhang H, Wang X, Xu P, et al. Tolfenamic acid inhibits GSK-3β and PP2A mediated tau hyperphosphorylation in Alzheimer's disease models. J Physiol Sci (2020). PMID: 32517647 DOI: 10.1186/s12576-020-00757-y Source material

Added to your cart

View Cart Checkout
Loading...